Christian Schade

Chris is a Senior Advisor on the Frazier Life Sciences team.

Chris joined the Frazier Life Sciences team in 2026 with over 30 years of experience across private and public biopharma companies as a seasoned executive.

Prior to joining Frazier Life Sciences, Chris was the President and Chief Executive Officer of Halda Therapeutics, a company developing a novel class of cancer therapies, until its $3.050 billion sale to Johnson & Johnson in December 2025. Prior to Halda, Chris was a Growth Partner at Flagship Pioneering.

Chris was President and Chief Executive Officer and Board member of Aprea Therapeutics (Nasdaq: APRE) from 2016 to 2022, including as Chairman from 2020 to 2023. He led Aprea in developing its pipeline of anti-cancer therapies through the company’s IPO in 2019. Chris has also served in executive leadership positions at several other biotech companies with emerging clinical candidates including: Chief Executive Officer of Novira, a privately held antiviral drug discovery company until it was acquired by Johnson & Johnson; Chief Financial Officer of Omthera Pharmaceuticals, Inc., a Nasdaq-listed specialty pharmaceuticals company focused on new therapies for dyslipidemia until it was acquired by AstraZeneca Plc; and, Senior Vice President of Administration and Chief Financial Officer at Medarex, Inc, a biopharmaceutical company focused on antibody-based therapeutic products for oncology, inflammation, autoimmune disorders, and infectious diseases until it was acquired by Bristol-Myers Squibb.

Earlier in his career, Chris was Managing Director at Merrill Lynch in London and for nearly 20 years held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JPMorgan.

Chris serves as a Director at Integra LifeSciences (Nasdaq: IART) where he chairs the Audit and Finance Committees. He received an A.B. degree from Princeton University and received an M.B.A. from the Wharton School at the University of Pennsylvania.